Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DBV Technologies (DBVT) Short term Debt (2014 - 2020)

DBV Technologies (DBVT) reported Short term Debt of $644354.2 for Q2 2020, little changed year-over-year from $642721.6 in Q3 2019, and up 0.89% on a QoQ basis from $638674.2 in Q4 2019.

DBV Technologies (DBVT) has 7 years of Short term Debt data on file, last reported at $644354.2 in Q2 2020.

  • Quarterly Short term Debt changed 0.25% year-over-year to $644354.2 in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $644354.2 (changed 0.25% YoY) and the FY2019 annual result came in at $638674.2, down 53.41% from the prior year.
  • Short term Debt grew to $644354.2 in Q2 2020 per DBVT's latest filing, from $638674.2 in the prior quarter.
  • Across five years, Short term Debt topped out at $2.7 million in Q4 2017 and bottomed at $506184.0 in Q2 2016.
  • The 5-year median for Short term Debt is $643537.9 (2019), against an average of $1.1 million.
  • The widest annual swing landed in 2017, when Short term Debt jumped 329.0%; it then tumbled 73.7% in 2019.
  • Tracing DBVT's Short term Debt over 5 years: stood at $638117.0 in 2016, then jumped by 329.0% to $2.7 million in 2017, then slumped by 49.93% to $1.4 million in 2018, then slumped by 53.41% to $638674.2 in 2019, then increased by 0.89% to $644354.2 in 2020.
  • Per Business Quant, the three latest DBVT Short term Debt figures stand at $644354.2 (Q2 2020), $638674.2 (Q4 2019), and $639819.8 (Q3 2019).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 DBV Technologies 8.00 Bn 7.77 Bn -3.90 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2020 644,354.18
Dec 31, 2019 638,674.19
Sep 30, 2019 639,819.77
Jun 30, 2019 642,721.56
Dec 31, 2018 1.37 Mn
Jun 30, 2018 2.44 Mn
Dec 31, 2017 2.74 Mn
Jun 30, 2017 800,471.90
Dec 31, 2016 638,117.02
Jun 30, 2016 506,184.01
Dec 31, 2015 163,321.47
Jun 30, 2015 164,568.80
Dec 31, 2014 265,884.58